AU2018422406A1 - Use of canakinumab - Google Patents

Use of canakinumab Download PDF

Info

Publication number
AU2018422406A1
AU2018422406A1 AU2018422406A AU2018422406A AU2018422406A1 AU 2018422406 A1 AU2018422406 A1 AU 2018422406A1 AU 2018422406 A AU2018422406 A AU 2018422406A AU 2018422406 A AU2018422406 A AU 2018422406A AU 2018422406 A1 AU2018422406 A1 AU 2018422406A1
Authority
AU
Australia
Prior art keywords
canakinumab
patient
hscrp
administration
lbeta
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2018422406A
Other languages
English (en)
Inventor
Linda Mindeholm
Jens PRAESTGAARD
Mattias SCHIEKER
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novartis AG
Original Assignee
Novartis AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis AG filed Critical Novartis AG
Publication of AU2018422406A1 publication Critical patent/AU2018422406A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • C07K16/245—IL-1
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Materials For Medical Uses (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
AU2018422406A 2018-05-09 2018-08-24 Use of canakinumab Abandoned AU2018422406A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862669071P 2018-05-09 2018-05-09
US62/669,071 2018-05-09
PCT/IB2018/056455 WO2019215484A1 (en) 2018-05-09 2018-08-24 Use of canakinumab

Publications (1)

Publication Number Publication Date
AU2018422406A1 true AU2018422406A1 (en) 2020-11-12

Family

ID=63638190

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2018422406A Abandoned AU2018422406A1 (en) 2018-05-09 2018-08-24 Use of canakinumab

Country Status (12)

Country Link
US (1) US20210371511A1 (enExample)
EP (1) EP3790576A1 (enExample)
JP (2) JP2021523894A (enExample)
KR (1) KR20210008847A (enExample)
CN (2) CN119746057A (enExample)
AU (1) AU2018422406A1 (enExample)
BR (1) BR112020022576A2 (enExample)
CA (1) CA3098277A1 (enExample)
CL (1) CL2020002881A1 (enExample)
MX (1) MX2020011909A (enExample)
TW (1) TW201946652A (enExample)
WO (1) WO2019215484A1 (enExample)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN112402359A (zh) * 2020-11-04 2021-02-26 深圳前海鹰岗生物科技有限公司 一种抑制细胞炎症因子治疗痛风急性发作的聚合物微针及制备方法

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0672142B1 (en) 1992-12-04 2001-02-28 Medical Research Council Multivalent and multispecific binding proteins, their manufacture and use
GB0020685D0 (en) * 2000-08-22 2000-10-11 Novartis Ag Organic compounds
PL2848258T3 (pl) 2005-10-26 2018-06-29 Novartis Ag Leczenie rodzinnej gorączki śródziemnomorskiej przeciwciałami przeciwko IL-1beta
HRP20251174T1 (hr) * 2010-11-05 2025-11-21 Novartis Ag Postupci za liječenje psorijatičnog artritisa uporabom il-17 antagonista
BR112014007253A2 (pt) * 2011-09-30 2017-03-28 Novartis Ag uso de anticorpos que se ligam a il-1beta
US20150203592A1 (en) * 2013-12-02 2015-07-23 Abbvie Inc. Compositions and methods for treating osteoarthritis
US9209965B2 (en) 2014-01-14 2015-12-08 Microsemi Semiconductor Ulc Network interface with clock recovery module on line card
UY37758A (es) * 2017-06-12 2019-01-31 Novartis Ag Método de fabricación de anticuerpos biespecíficos, anticuerpos biespecíficos y uso terapéutico de dichos anticuerpos
AU2018287519B2 (en) * 2017-06-22 2021-07-22 Novartis Ag IL-1beta binding antibodies for use in treating cancer
CN107723310B (zh) * 2017-10-19 2024-01-09 北京睿诚海汇健康科技有限公司 植物作为宿主在表达卡那抗体中的应用

Also Published As

Publication number Publication date
BR112020022576A2 (pt) 2021-02-09
MX2020011909A (es) 2021-01-29
TW201946652A (zh) 2019-12-16
KR20210008847A (ko) 2021-01-25
CL2020002881A1 (es) 2021-05-14
JP2023071904A (ja) 2023-05-23
CA3098277A1 (en) 2019-11-14
WO2019215484A1 (en) 2019-11-14
EP3790576A1 (en) 2021-03-17
US20210371511A1 (en) 2021-12-02
JP2021523894A (ja) 2021-09-09
JP7713983B2 (ja) 2025-07-28
CN119746057A (zh) 2025-04-04
CN112584857A (zh) 2021-03-30

Similar Documents

Publication Publication Date Title
JP6515168B2 (ja) Ｉｌ−１７アンタゴニストを用いて関節リウマチを治療する方法
JP7341996B2 (ja) Ｉｌ－１７アンタゴニストを用いて化膿性汗腺炎を治療すること
AU2024202601A1 (en) Method of treating tendinopathy using interleukin-17 (IL-17) antagonists
JP7713983B2 (ja) カナキヌマブの使用
KR20200051706A (ko) 비알콜성 지방간염 (nash)을 치료하는 방법에 사용하기 위한 변형된 섬유모세포 성장 인자 21 (fgf-21)
JP2025516723A (ja) インターロイキン－１７（ｉｌ－１７）アンタゴニストを使用して腱障害を選択的に治療する方法
TW202434624A (zh) 治療或預防甲狀腺素運載蛋白調節之澱粉樣變性的方法
AU2016272900A1 (en) Use of IL-1 beta binding antibodies to treat peripheral arterial disease
CA3062179A1 (en) Methods of selectively treating asthma using il-17 antagonists
WO2020039401A1 (en) Treatment comprising il-1βeta binding antibodies and combinations thereof
Morgado Internship Reports and Monograph entitled “Pharmacokinetic Monitorization of Monoclonal Antibodies: The example of Infliximab in Inflammatory Bowel Diseases”
WO2025083621A1 (en) Treatment of hidradenitis suppurativa using anti-baff-r antibodies
Espinosa et al. Pediatric Rheumatology

Legal Events

Date Code Title Description
MK4 Application lapsed section 142(2)(d) - no continuation fee paid for the application